{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-286826","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2023-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.231602+00:00","generated_at":"2026-06-07T19:19:06.194156+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Apellis updates SYFOVRE label to include rare retinal vasculitis risk; rate 0.01% per injection","bullets":["Updated USPI Warnings/Precautions and Postmarketing Experience sections to include retinal vasculitis with/without occlusion.","Estimated rate of retinal vasculitis remains rare at 0.01% per injection, based on over 120,000 injections administered as of Nov 18, 2023.","Label update pursued in collaboration with the FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-286826","json":"https://secwatch.observer/filing/0001193125-23-286826.json","markdown":"https://secwatch.observer/filing/0001193125-23-286826.md","text":"https://secwatch.observer/filing/0001193125-23-286826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523286826/0001193125-23-286826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523286826/d616555d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T19:19:06.194156+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}